Published on
June 1, 2023
- 18:34 GMT
Dosing of CLK Inhibitor CTX-712 Starts in Patients with Relapsed or Refractory AML or MDS in the U.S.
Chordia announces first patient dosed in the Phase 1/2 study with Relapsed or Refractory acute myeloid leukemia or myelodysplastic syndrome in the U.S. FUJISAWA, KANAGAWA, JAPAN, June 1, 2023 /EINPresswire.com/ -- Chordia Therapeutics Inc. (“Chordia”), …
Distribution channels:
Healthcare & Pharmaceuticals Industry
...
